Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ofwat confirms Thames Water actions after firm's credit downgrade

(Sharecast News) - Water regulator Ofwat confirmed the immediate implementation of new measures on Friday, to address Thames Water's recent loss of its investment-grade credit ratings. The action followed a public consultation, and would involve several critical steps designed to improve the company's financial and operational stability.

Key among the measures was the appointment of an independent monitor to closely track Thames Water's progress, particularly in relation to its ongoing transformation plan.

The regulator said the monitor would report back to Ofwat regularly, and would have full access to the company's internal information.

Thames Water was also required to develop and implement a robust operational business plan aimed at turning around its performance.

Additionally, the company was required to execute an equity raise to strengthen its financial position.

Additionally, Thames Water's board would see the introduction of new non-executive directors as part of the commitments.

The measures would remain in force until the company successfully regained two investment-grade credit ratings, Ofwat said.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.